Financial Contrast: Brenntag (OTCMKTS:BNTGY) and Avivagen (OTCMKTS:VIVXF)

Brenntag (OTCMKTS:BNTGY) and Avivagen (OTCMKTS:VIVXF) are both basic materials companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Volatility and Risk

Brenntag has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Avivagen has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500.

Profitability

This table compares Brenntag and Avivagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Brenntag	3.36%	12.24%	4.99%
Avivagen	N/A	N/A	N/A

Earnings and Valuation

This table compares Brenntag and Avivagen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brenntag	$18.20 billion	0.50	$773.74 million	$0.80	15.84
Avivagen	$730,000.00	0.00	-$4.71 million	N/A	N/A

Brenntag has higher revenue and earnings than Avivagen.

Analyst Ratings

This is a breakdown of current ratings for Brenntag and Avivagen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brenntag	0	3	0	1	2.50
Avivagen	0	0	0	0	0.00

Given Avivagen’s higher possible upside, analysts clearly believe Avivagen is more favorable than Brenntag.

Summary

Brenntag beats Avivagen on 8 of the 9 factors compared between the two stocks.

About Brenntag

Brenntag SE purchases and supplies various industrial and specialty chemicals, and ingredients in Germany, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company operates in two segments, Brenntag Essentials and Brenntag Specialties. It provides just-in-time delivery, product mixing, blending, repackaging, inventory management, and drum return handling. The company serves customers in various end-market industries, including nutrition, pharma, personal care, water treatment, and lubricants; and home, industrial, and institutional markets, as well as coatings and constructions, polymers, and rubber industries. The company was founded in 1874 and is based in Essen, Germany.

About Avivagen

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.